Suppr超能文献

不同肾功能程度患者静脉注射环丙沙星的药代动力学

Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.

作者信息

Drusano G L, Weir M, Forrest A, Plaisance K, Emm T, Standiford H C

出版信息

Antimicrob Agents Chemother. 1987 Jun;31(6):860-4. doi: 10.1128/AAC.31.6.860.

Abstract

We examined the pharmacokinetic behavior of 200 mg of ciprofloxacin administered intravenously to 32 volunteers whose renal function as measured by creatinine clearance ranged from 0 to 8.99 liters/h per 1.73 m2. Serum clearances (mean +/- standard deviation) were 26.8 +/- 5.7 and 15.4 +/- 4.3 liters/h per 1.73 m2 in normal and anephric volunteers, respectively. The half-life (mean +/- standard deviation) increased from 4.3 +/- 0.8 h in normal volunteers to 8.6 +/- 3.3 h in anephric volunteers. There was good correlation between normalized creatinine clearance and both normalized serum and renal clearance. The regression equation for serum clearance (CLS) versus creatinine clearance (CLCR) was CLS = 1.97 X CLCR + 13.23, where r = 0.697; for renal clearance versus creatinine clearance, the equation was CLR = 2.26 X CLCR, where r = 0.845. On the basis of these data, we recommend a maximum 50% reduction in dose when ciprofloxacin is instituted at a renal function of 1.2 to 1.8 liters/h per 1.73 m2 (20 to 30 ml/min per 1.73 m2). Because of the observed variation in ciprofloxacin half-life in our anephric volunteers, we also recommend that a schedule of administration every 12 h be maintained, even for patients without urine output.

摘要

我们研究了静脉注射200毫克环丙沙星在32名志愿者体内的药代动力学行为,这些志愿者的肌酐清除率所测肾功能范围为每1.73平方米0至8.99升/小时。正常志愿者和无肾志愿者的血清清除率(平均值±标准差)分别为每1.73平方米26.8±5.7升/小时和15.4±4.3升/小时。半衰期(平均值±标准差)从正常志愿者的4.3±0.8小时增加到无肾志愿者的8.6±3.3小时。标准化肌酐清除率与标准化血清清除率和肾清除率之间均具有良好的相关性。血清清除率(CLS)与肌酐清除率(CLCR)的回归方程为CLS = 1.97×CLCR + 13.23,其中r = 0.697;肾清除率与肌酐清除率的方程为CLR = 2.26×CLCR,其中r = 0.845。基于这些数据,我们建议当环丙沙星用于肾功能为每1.73平方米1.2至1.8升/小时(每1.73平方米20至30毫升/分钟)的患者时,最大剂量减少50%。由于在我们的无肾志愿者中观察到环丙沙星半衰期存在差异,我们还建议即使对于无尿患者也维持每12小时一次的给药方案。

相似文献

1
Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.
Antimicrob Agents Chemother. 1987 Jun;31(6):860-4. doi: 10.1128/AAC.31.6.860.
3
Relationships between renal function and disposition of oral ciprofloxacin.
Antimicrob Agents Chemother. 1988 Oct;32(10):1537-40. doi: 10.1128/AAC.32.10.1537.
4
Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
J Antimicrob Chemother. 1996 Jul;38(1):103-16. doi: 10.1093/jac/38.1.103.
5
Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function.
Antimicrob Agents Chemother. 1987 May;31(5):709-12. doi: 10.1128/AAC.31.5.709.
6
Effect of renal function on the bioavailability of ciprofloxacin.
Antimicrob Agents Chemother. 1990 Jun;34(6):1031-4. doi: 10.1128/AAC.34.6.1031.
7
Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.
Antimicrob Agents Chemother. 1989 Nov;33(11):1952-7. doi: 10.1128/AAC.33.11.1952.
8
Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function.
Antimicrob Agents Chemother. 1983 Aug;24(2):151-5. doi: 10.1128/AAC.24.2.151.
9
Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:83-7. doi: 10.1093/jac/18.supplement_d.83.
10
Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.
Antimicrob Agents Chemother. 1993 May;37(5):1065-72. doi: 10.1128/AAC.37.5.1065.

引用本文的文献

5
Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients.
Eur J Clin Pharmacol. 2020 Jul;76(7):957-967. doi: 10.1007/s00228-020-02873-5. Epub 2020 Apr 19.
6
7
Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs.
Clin Pharmacokinet. 2018 Apr;57(4):505-514. doi: 10.1007/s40262-017-0574-9.
9
Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients.
Antimicrob Agents Chemother. 2001 Oct;45(10):2949-54. doi: 10.1128/AAC.45.10.2949-2954.2001.
10
Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.
Clin Pharmacokinet. 2001;40(3):169-87. doi: 10.2165/00003088-200140030-00003.

本文引用的文献

1
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.
Antimicrob Agents Chemother. 1984 Mar;25(3):331-5. doi: 10.1128/AAC.25.3.331.
2
Absolute oral bioavailability of ciprofloxacin.
Antimicrob Agents Chemother. 1986 Sep;30(3):444-6. doi: 10.1128/AAC.30.3.444.
3
Dose ranging study and constant infusion evaluation of ciprofloxacin.
Antimicrob Agents Chemother. 1986 Sep;30(3):440-3. doi: 10.1128/AAC.30.3.440.
4
Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis.
Antimicrob Agents Chemother. 1986 Jul;30(1):152-6. doi: 10.1128/AAC.30.1.152.
5
The pharmacokinetics of ciprofloxacin in patients with impaired renal function.
J Antimicrob Chemother. 1985 Jul;16(1):87-93. doi: 10.1093/jac/16.1.87.
6
A program package for simulation and parameter estimation in pharmacokinetic systems.
Comput Programs Biomed. 1979 Mar;9(2):115-34. doi: 10.1016/0010-468x(79)90025-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验